Reference health
Cost-Effectiveness of Interventions for the Prevention and Control of COVID-19: A Systematic Review and Meta-Analysis
49/49 checkable references clean · checked 2026-08-27
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
31 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 49 checked references that resolve
resolves10.1016/S2213-2600(20)30076-X
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
resolves10.1038/s41380-020-00875-4
The COVID-19 pandemic and epidemiologic insights from recession-related suicide mortality
resolves10.1377/hlthaff.2020.00426
The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States
resolves10.1016/S0140-6736(20)31022-9
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
resolves10.1016/S0140-6736(20)31142-9
Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis
resolves10.1016/S0140-6736(20)31605-6
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
resolves10.1038/s41586-020-2405-7
Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe
resolves10.1016/S2214-109X(20)30452-6
Cost-effectiveness of public health strategies for COVID-19 epidemic control in South Africa: a microsimulation modelling study
resolves10.1111/ijcp.13674
“Stay at Home, Protect the National Health Service, Save Lives”: A cost benefit analysis of the lockdown in the United Kingdom
resolves10.3126/nje.v11i1.36163
Development and implementation of a potential coronavirus disease 2019 (COVID-19) vaccine: A systematic review and meta-analysis of vaccine clinical trials
resolves10.1136/bmjopen-2020-048416
Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis
resolves10.1016/j.jval.2020.07.002
Cost-Effectiveness of Antiviral Treatments for Pandemics and Outbreaks of Respiratory Illnesses, Including COVID-19: A Systematic Review of Published Economic Evaluations
resolves10.1016/j.ijsu.2020.11.015
Economic evaluation of programs against COVID-19: A systematic review
resolves10.1186/1471-2288-14-139
Comparative efficiency research (COMER): meta-analysis of cost-effectiveness studies
resolves10.1016/j.jval.2019.09.2750
Cost Utility of Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Metformin Monotherapy Failed Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis
resolves10.1007/s10198-021-01275-3
Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations
resolves10.1016/j.jval.2013.02.002
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
resolves10.1001/jamanetworkopen.2020.28195
Clinical Outcomes, Costs, and Cost-effectiveness of Strategies for Adults Experiencing Sheltered Homelessness During the COVID-19 Pandemic
resolves10.1016/j.amepre.2021.01.001
The Benefits of Vaccinating With the First Available COVID-19 Coronavirus Vaccine
resolves10.1016/S2468-2667(21)00002-5
Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study
resolves10.1016/j.vaccine.2020.12.078
The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization
resolves10.1007/s10640-020-00440-1
Effects of Physical Distancing to Control COVID-19 on Public Health, the Economy, and the Environment
resolves10.1080/13696998.2021.1965732
Economic value of vaccines to address the COVID-19 pandemic: a U.S. cost-effectiveness and budget impact analysis
resolves10.7326/M21-0510
Clinical and Economic Effects of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission
resolves10.1001/jamanetworkopen.2020.16818
Assessment of SARS-CoV-2 Screening Strategies to Permit the Safe Reopening of College Campuses in the United States
resolves10.1055/s-0040-1713647
Preventing COVID-19 Transmission on Labor and Delivery: A Decision Analysis
resolves10.1017/bca.2020.12
The Benefits and Costs of Using Social Distancing to Flatten the Curve for COVID-19
resolves10.1371/journal.pone.0252729
The benefits of coronavirus suppression: A cost-benefit analysis of the response to the first wave of COVID-19 in the United States
resolves10.1016/S1473-3099(21)00079-7
The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation
resolves10.1016/j.jval.2020.07.001
Costing the COVID-19 Pandemic: An Exploratory Economic Evaluation of Hypothetical Suppression Policy in the United Kingdom
resolves10.1186/s12913-021-06081-4
Cost‐effectiveness of intensive care for hospitalized COVID-19 patients: experience from South Africa
resolves10.1136/bmjgh-2020-002690
The cost-effectiveness of conducting three versus two reverse transcription-polymerase chain reaction tests for diagnosing and discharging people with COVID-19: evidence from the epidemic in Wuhan, China
resolves10.1016/j.jval.2020.12.009
Disease Burden Attributable to the First Wave of COVID-19 in China and the Effect of Timing on the Cost-Effectiveness of Movement Restriction Policies
resolves10.1016/j.jval.2020.09.013
Modeling Social Distancing Strategies to Prevent SARS-CoV-2 Spread in Israel: A Cost-Effectiveness Analysis
resolves10.1007/s40258-020-00632-2
How Many Intensive Care Beds are Justifiable for Hospital Pandemic Preparedness? A Cost-effectiveness Analysis for COVID-19 in Germany
resolves10.1016/j.chaos.2020.110438
Optimal control approach of a mathematical modeling with multiple delays of the negative impact of delays in applying preventive precautions against the spread of the COVID-19 pandemic with a case study of Brazil and cost-effectiveness
resolves10.1016/j.chaos.2020.110364
Analyzing the impact of the media campaign and rapid testing for COVID-19 as an optimal control problem in East Java, Indonesia
resolves10.1016/j.ijid.2020.08.025
The costs of an expanded screening criteria for COVID-19: A modelling study
resolves10.3390/vaccines9040399
COVID-19 Vaccination Scenarios: A Cost-Effectiveness Analysis for Turkey
resolves10.1093/trstmh/traa140
The benefits and costs of social distancing in high- and low-income countries
resolves10.1055/a-1294-0427
Cost-effectiveness analysis of SARS-CoV-2 infection prevention strategies including pre-endoscopic virus testing and use of high risk personal protective equipment
resolves10.1371/journal.pone.0240503
Cost-effectiveness and return on investment of protecting health workers in low- and middle-income countries during the COVID-19 pandemic
resolves10.1016/j.jaip.2021.02.054
A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated with Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies
resolves10.1007/s12325-021-01654-5
A Cost-Effectiveness Framework for COVID-19 Treatments for Hospitalized Patients in the United States
resolves10.1126/science.abc0035
The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries
resolves10.24171/j.phrp.2020.11.1.09
Contact Transmission of COVID-19 in South Korea: Novel Investigation Techniques for Tracing Contacts
resolves10.1016/S0140-6736(20)32661-1
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
The 31 references without a DOI — listed, not checked
no DOI — not checkedref3
no DOI — not checkedQuantifying the impact of COVID-19 non-pharmaceutical interventions on influenza transmission in the United States
no DOI — not checkedRisk-Assessment of Hospitalized Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Patients Using Laboratory Data and Immune Cell Morphological Assessment
no DOI — not checkedref7
no DOI — not checkedEconomic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios
no DOI — not checkedCOVID-19: Government subsidy models for sustainable energy supply with disruption risks
no DOI — not checkedEffectiveness of Telerehabilitation in Physical Therapist Practice: An Umbrella and Mapping Review With Meta-Meta-Analysis
no DOI — not checkedPreferred reporting items for systematic review and metaanalysis protocols (PRISMA-P) 2015: elaboration and explanation
no DOI — not checkedLives and Costs Saved by Expanding and Expediting COVID-19 Vaccination
no DOI — not checkedClinical Impact, Costs, and Cost-Effectiveness of Expanded SARS-CoV-2 Testing in Massachusetts
no DOI — not checkedAssessing the Optimality of a COVID Lockdown in the United States
no DOI — not checkedPotential health and economic impacts of dexamethasone treatment for patients with COVID-19
no DOI — not checkedHow fast should social restrictions be eased in England as COVID-19 vaccinations are rolled out?
no DOI — not checkedCombination therapy with tocilizumab and dexamethasone cost-effectively reduces Coronavirus disease 2019 mortality
no DOI — not checkedref47
no DOI — not checkedref48
no DOI — not checkedref52
no DOI — not checkedref53
no DOI — not checkedGandjour A. The Clinical and Economic Value of a Successful Shutdown During the SARS-CoV-2 Pandemic in Germany
no DOI — not checkedref56
no DOI — not checkedAsymptomatic Mass Testing Strategy in the North Metropolitan Area of Barcelona
no DOI — not checkedSimplified Mathematical Modelling of Uncertainty: Cost-Effectiveness of COVID-19 Vaccines in Spain
no DOI — not checkedA Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine
no DOI — not checkedGlobal stability and costeffectiveness analysis of COVID-19 considering the impact of the environment: using data from Ghana
no DOI — not checkedCost-effectiveness of surgical mask, N-95 respirator, hand-hygiene and surgical mask with hand hygiene in the prevention of COVID-19: Cost effectiveness analysis from Indian context
no DOI — not checkedAnalysis of COVID-19 and comorbidity co-infection model with optimal control
no DOI — not checkedA benefit-cost analysis of different response scenarios to COVID-19: A case study
no DOI — not checkedA multi-region discrete time mathematical modeling of the dynamics of Covid-19 virus propagation using optimal control
no DOI — not checkedref74
no DOI — not checkedref75
no DOI — not checkedSymptomatic and optimal supportive care of critical COVID-19: A case report and literature review
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-08-27 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.2139/ssrn.3944593"><img src="https://citestamp.com/citestamped/10.2139/ssrn.3944593/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.2139/ssrn.3944593)